company background image
SMTI logo

Sanara MedTech NasdaqCM:SMTI Stock Report

Last Price

US$32.64

Market Cap

US$285.3m

7D

1.3%

1Y

-11.5%

Updated

19 Jan, 2025

Data

Company Financials +

Sanara MedTech Inc.

NasdaqCM:SMTI Stock Report

Market Cap: US$285.3m

SMTI Stock Overview

A medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. More details

SMTI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Sanara MedTech Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sanara MedTech
Historical stock prices
Current Share PriceUS$32.64
52 Week HighUS$40.75
52 Week LowUS$26.00
Beta1.55
1 Month Change-3.09%
3 Month Change-2.48%
1 Year Change-11.52%
3 Year Change47.83%
5 Year Change63.28%
Change since IPO-96.52%

Recent News & Updates

Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt

Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Recent updates

Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt

Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump

Sep 05
Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump

Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt

Aug 14
Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt

Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story

May 23
Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story

Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?

Nov 15
Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?

Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)

May 22
Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Mar 22
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Sep 06

Sanara MedTech reports Q2 results

Aug 15

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Dec 31
Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Sanara MedTech: Technology For Faster Healing Wounds

Dec 08

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Jun 04

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

May 18
Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

Neil Cataldi From Blueprint Discusses Sanara MedTech

May 03

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

Feb 19
The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Dec 28
Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Shareholder Returns

SMTIUS Medical EquipmentUS Market
7D1.3%3.7%3.2%
1Y-11.5%12.3%24.0%

Return vs Industry: SMTI underperformed the US Medical Equipment industry which returned 12.3% over the past year.

Return vs Market: SMTI underperformed the US Market which returned 24% over the past year.

Price Volatility

Is SMTI's price volatile compared to industry and market?
SMTI volatility
SMTI Average Weekly Movement5.6%
Medical Equipment Industry Average Movement8.7%
Market Average Movement6.5%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: SMTI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SMTI's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001108Ron Nixonsanaramedtech.com

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution.

Sanara MedTech Inc. Fundamentals Summary

How do Sanara MedTech's earnings and revenue compare to its market cap?
SMTI fundamental statistics
Market capUS$285.31m
Earnings (TTM)-US$8.36m
Revenue (TTM)US$78.06m

3.7x

P/S Ratio

-34.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SMTI income statement (TTM)
RevenueUS$78.06m
Cost of RevenueUS$7.68m
Gross ProfitUS$70.38m
Other ExpensesUS$78.74m
Earnings-US$8.36m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin90.16%
Net Profit Margin-10.71%
Debt/Equity Ratio76.2%

How did SMTI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 03:09
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sanara MedTech Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ross OsbornCantor Fitzgerald & Co.
Yi ChenH.C. Wainwright & Co.